Chemotherapy with or without silibinin for newly diagnosed blood cancer
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding silibinin (a plant-based supplement) to standard chemotherapy drugs (daunorubicin or idarubicin) helps treat newly diagnosed acute myeloid leukemia (AML), a serious blood cancer. The goal is to see if this combination is more effective and safer than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed acute myeloid leukemia (AML, excluding a specific subtype called M3) confirmed by recent blood/bone marrow tests
- Your doctor believes you are healthy enough to tolerate standard chemotherapy drugs like daunorubicin or idarubicin
- Your doctor expects you to live at least 3 more months
- You are not pregnant, breastfeeding, or have untreated HIV
- You do not have severe liver disease, uncontrolled bleeding disorders, or other serious uncontrolled medical conditions
- You have not been in another clinical trial in the past month and are able to follow the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called BL-M11D1 combined with standard chemotherapy (cytarabine + daunorubicin) or a targeted therapy (venetoclax + azacitidine) for people with newly diagnosed acute myeloid leukemia (AML). It aims to see if this combination is safe and effective.
This trial adds an experimental drug called bleximenib to the usual chemotherapy for people newly diagnosed with AML who have certain genetic changes (NPM1 or KMT2A). The goal is to see if adding this drug helps the treatment work better.
This trial tests a combination of two chemotherapy drugs (idarubicin and cytarabine) at lower doses plus a targeted drug called venetoclax for adults newly diagnosed with acute myeloid leukemia or high-risk myelodysplastic syndrome. The goal is to see if this reduced-intensity treatment is effective with fewer side effects.
This trial tests whether one initial chemotherapy approach works better than another in people newly diagnosed with high-risk acute myeloid leukemia (AML). You may benefit if your disease is high-risk, and the study will also compare how well the treatments control the leukemia and how safely they work.
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
This trial tests a combination of three drugs—daunorubicin, cytarabine, and venetoclax—for people with newly diagnosed AML who are strong enough to receive intensive chemotherapy. The goal is to see if adding venetoclax helps improve treatment outcomes.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.